Surface Oncology is a clinical-stage company that develops cancer therapies through the use of various antibodies. Some of their antibody research includes targeting molecules that help to produce adenosine or that inhibit enzymatic activity that breaks down adenosine. They hold license agreements allowing them to develop, produce and commercialize certain antibodies with other companies. The company was founded in 2014 and has its headquarters in Cambridge, Massachusetts.